AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review

Icariin against neuroinflammation: emerging evidence for gut-brain axis modulation involving short-chain fatty acids, vagal signaling, and extracellular vesicles

Changzheng Wua, Lijiao Guob, Xiaoyu Suna,c, Jinpu Zhua,c, Zhehao Zhaoa, Shuo Qia, Yaru Lia, Hongyang Lid, Renshuang Zhaoe, Zhiru Xiuf( ), Guangze Zhua,b( ), Yiquan Lia( )
Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun 130117, China
Department of Clinical Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130117, China
Children’s Diagnosis and Treatment Center, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130117, China
Department of Transfusion Medicine, China-Japan Union Hospital of Jilin University, Changchun 130033, China
College of Animal Science, Zhejiang University, Hangzhou 310013, China
Stem Cell Clinical Research Center, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China
Show Author Information

Abstract

Neuroinflammation is a central pathological process in a wide range of central nervous system disorders, yet therapeutic strategies directed solely at single inflammatory targets have shown limited efficacy. Gut–brain axis dysfunction may contribute to neuroinflammatory progression through interconnected metabolic, immune, neural, and vesicle-associated routes. Icariin, a major flavonoid glycoside from Epimedii Folium, has attracted attention because of its anti-inflammatory, neuroprotective, and microbiota-modulating properties. In this review, we summarize current evidence for the anti-neuroinflammatory effects of icariin and explicitly stratify the evidence into three levels: direct icariin-related findings, icariin-related findings without causal gut–brain validation, and mechanisms inferred from broader gut–brain axis biology. Available studies provide relatively stronger support for intestinal barrier protection, microbiota remodeling, peripheral cytokine suppression, and central inflammatory pathway regulation. In contrast, short-chain fatty acid (SCFA)-associated signaling, vagal neuroimmune communication, and extracellular vesicle (EV)-mediated cargo transfer remain plausible but incompletely validated candidate routes. We further compare icariin with its major microbial metabolites, especially icariside II and icaritin, because oral icariin may act partly through metabolite-mediated exposure rather than through robust brain penetration of the parent compound. Major limitations include insufficient causal perturbation, incomplete organ-specific pharmacokinetic data, inter-individual microbiota variability, and uncertain therapeutic time windows. Overall, icariin emerges as a promising multi-target natural product for anti-neuroinflammatory research, but the causal hierarchy and translational relevance of proposed gut–brain pathways require direct validation.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1294-1309

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wu C, Guo L, Sun X, et al. Icariin against neuroinflammation: emerging evidence for gut-brain axis modulation involving short-chain fatty acids, vagal signaling, and extracellular vesicles. Chinese Journal of Natural Medicines, 2026, 24(11): 1294-1309. https://doi.org/10.1016/S1875-5364(26)61221-6

3

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 21 March 2026
Revised: 26 July 2026
Accepted: 13 August 2026
Published: 20 November 2026
© 2026, China Pharmaceutical University.